Sohanya Roshan Cheng

CIK: 0001865796

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (58.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KPTI

Karyopharm Therapeutics Inc.

Officer

CARM

Carisma Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

KPTI
Karyopharm Therapeutics Inc.
May 14, 2026
Sale(S)
Direct
324 shares at avg. $9.50$3K
KPTI
Karyopharm Therapeutics Inc.
May 13, 2026
Award(A)
Direct
947 shares-
KPTI
Karyopharm Therapeutics Inc.
Mar 2, 2026
Sale(S)
Direct
4.6K shares at avg. $9.41$43K
KPTI
Karyopharm Therapeutics Inc.
Jan 31, 2026
Award(A)
Direct
32.4K shares-
KPTI
Karyopharm Therapeutics Inc.
Oct 15, 2025
Award(A)
Direct
43.7K shares-
KPTI
Karyopharm Therapeutics Inc.
Sep 15, 2025
Sale(S)
Direct
325 shares at avg. $6.43$2K
KPTI
Karyopharm Therapeutics Inc.
Sep 12, 2025
Award(A)
Direct
945 shares-
KPTI
Karyopharm Therapeutics Inc.
Mar 4, 2025
Sale(S)
Direct
3.4K shares at avg. $6.29$22K
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
5.4K shares-
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
4.6K shares-
CARM
Carisma Therapeutics Inc.
Oct 31, 2024
Award(A)
Stock Option (Right to Buy)
Direct
38.7K shares-
KPTI
Karyopharm Therapeutics Inc.
Sep 4, 2024
Sale(S)
Direct
5.4K shares at avg. $0.72$4K

		Type	Shares	Price		Ownership
May 14, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	324	$9.50	$3,078	Direct
May 13, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	947	-	$0	Direct
Mar 2, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	4,604	$9.41	$43,321	Direct
Jan 31, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	32,415	-	$0	Direct
Oct 15, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	43,650	-	-	Direct
Sep 15, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	325	$6.43	$2,090	Direct
Sep 12, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	945	-	-	Direct
Mar 4, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	3,445	$6.29	$21,669	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	5,416	-	-	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	4,583	-	-	Direct
Oct 31, 2024	CARM Carisma Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	38,700	-	-	Direct
Sep 4, 2024	KPTI Karyopharm Therapeutics Inc.	Sale(S)	5,356	$0.72	$3,866	Direct

1-12 of 12 transactions

About Cheng Sohanya Roshan

Cheng Sohanya Roshan (SEC CIK 0001865796) files insider reports with the SEC as EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc. (KPTI) and Director of Carisma Therapeutics Inc. (CARM).

Signal8 holds 10 ownership filings by Cheng Sohanya Roshan (1 Form 3, 9 Form 4), filed between Sep 5, 2024 and May 15, 2026. Those filings report 12 transactions, from Sep 4, 2024 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cheng Sohanya Roshan's filings is in NEWTON, MA.

Recent filings by Cheng Sohanya Roshan

May 14, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 13, 2026: Grant or award of KPTI shares (Form 4, code A).
Mar 2, 2026: Open-market sale of KPTI shares (Form 4, code S).
Jan 31, 2026: Grant or award of KPTI shares (Form 4, code A).
Oct 15, 2025: Grant or award of KPTI shares (Form 4, code A).

Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)

Abate Kristin, Chief Accounting Officer
Poulton Stuart, EVP, Chief Development Officer
Oliger Christy J., Director
PAKIANATHAN DEEPIKA, Director
Schor Chen, Director
Su Zhen, Director

How to read Form 4 transaction codes